Procedure Enabled by Innovative Cardica Technology to be Featured at STS/AATS Tech-Con 2016
January 21 2016 - 4:34PM
Cardica, Inc. (Nasdaq:CRDC) today announced the company’s
MicroCutter XCHANGE® 30 surgical stapler, with a shaft diameter of
5 millimeters and the capability to articulate 80 degrees, will be
featured in a presentation describing a cutting-edge lobectomy
technique at The Society of Thoracic Surgeons and American
Association for Thoracic Surgery’s Tech Conference (Tech-Con) to be
held January 23-24 in Phoenix, Ariz.
Tech-Con focuses on cutting-edge devices and procedures that
have not yet been widely adopted by cardiothoracic surgeons.
A “Lung Surgery of the Future” presentation by Joel Dunning,
M.D., cardiothoracic surgeon at James Cook University Hospital,
Department of Cardiothoracic Surgery in Middlesbrough, U.K., will
describe Microlobectomy, the less-invasive technique Dr. Dunning
pioneered for video-assisted lung surgery, or VATS, which is
enabled by Cardica’s MicroCutter XCHANGE 30.
Dr. Dunning’s presentation, titled, “Microlobectomy: A Novel
Form of Video-Assisted Thoracoscopic Lobectomy,” is scheduled at
2:05 p.m. MST, Saturday January 23, in room 120D in the Phoenix
Convention Center.
About the MicroCutter XCHANGE 30The MicroCutter
XCHANGE 30, the world’s first and only five-millimeter surgical
stapler that articulates to 80 degrees, is a cartridge-based
minimally invasive surgical stapling system. The device’s small
size and articulation range is designed to enhance the surgeon’s
access and visualization at the surgical site, and to mitigate
limitations on the advancement of minimally invasive surgical
approaches created by larger stapling devices. As the
smallest-profile articulating stapler available today, the
MicroCutter XCHANGE 30 may reduce the amount of dissection and
tissue handling required to position the stapler in confined
spaces, enabling access to difficult-to-reach
anatomy.
About CardicaCardica designs and
manufactures proprietary stapling and anastomotic devices for
cardiac and minimally invasive surgical procedures. Cardica's
technology portfolio is intended to reduce operating time and
facilitate minimally invasive and robot-assisted surgeries.
Cardica’s MicroCutter XCHANGE® 30, that includes a cartridge-based
articulating surgical stapling device with a five-millimeter shaft
diameter and staples, is manufactured and cleared for use in the
United States for transection and resection in multiple open or
minimally invasive urologic, thoracic and pediatric surgical
procedures, as well as application for transection, resection
and/or creation of anastomoses in the small and large intestine and
the transection of the appendix. The MicroCutter XCHANGE 30 White
Cartridge staple has application in vascular tissue. In
addition, Cardica manufactures and markets its automated
anastomosis systems, the C-Port® Distal Anastomosis Systems and
PAS-Port® Proximal Anastomosis System for coronary artery bypass
graft (CABG) surgery, and has shipped over 56,500 units throughout
the world.
Forward-Looking StatementsThe statements in
this press release regarding Cardica’s beliefs as to the benefits
expected to be obtained from the use of the MicroCutter XCHANGE®
30, are "forward-looking statements." There are a number of
important factors that could cause results to differ materially
from those indicated by these forward-looking statements,
including: that Cardica may not be successful in its efforts to
complete the development of its combination device (designed to use
two different size cartridges) or achieve optimization of Cardica’s
supply chain for its combination device; that Cardica may not
receive regulatory approval for indications not currently approved;
as well as other risks detailed from time to time in Cardica’s
reports filed with the U.S. Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2015, under the caption “Risk Factors,” filed on
November 12, 2015. Cardica expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to
read Cardica’s reports filed with the U.S. Securities and Exchange
Commission, available at www.sec.gov.
Contact:
Bob Newell
Vice President, Finance and Chief Financial Officer
(650) 331-7133
investors@cardica.com